The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Pfizer ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

Pfizer (PFE) stock was up on Monday despite the pharmaceutical company ending the clinical trial of its once-daily GLP-1 weight loss pill, ...

We recently published a list of the 11 Best Dividend Paying Stocks According to Hedge Funds. In this article, we are going to ...

Im Ringen um den stark umkämpften Markt für Adipositas-Medikamente hat der US-Pharmakonzern Pfizer einen Rückschlag erlitten ...

Pfizer will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to ...